<unk>  (also known as<unk>  is a rare, mature T-cell<unk>  with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin.<unk>  was first described by Catovsky in 1973. There is no classification system for<unk> . The inversion of chromosome 14 (14q11) has been associated with the development of<unk> .<unk>  is very rare, and it represents 2% of all small lymphocytic<unk> s in adults.<unk>  is more commonly observed among young adult patients aged between 30 to 40 years old. Males are slightly more affected with are more commonly affected with<unk>  than females. Laboratory findings consistent with the diagnosis of<unk> , include high lymphocyte count (> 100 x 109/L), anemia, thrombocytopenia, and negative HTLV-1 serology. There are no specific imaging findings associated with<unk> . Prognosis is generally poor, and the median survival time of patients with<unk>  is approximately 7 months. The mainstay of therapy for<unk>  is alemtuzumab (anti-CD52). However,<unk>  is often resistant to therapy. Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission.
T-cell prolymphocytic leukemia
Aggressive NK-cell leukemia
B-cell prolymphocytic leukemia
Adult T-cell leukemia
T-cell large granular lymphocyte leukemia
Prolymphocytic leukemia
T-cell leukemia
B-cell leukemia